Evaluating Efgartigimod Therapy for Patients with IVIG-Dependent Acetylcholine Receptor Antibody Positive Myasthenia Gravis
Led by Clinique Neuro-Outaouais · Updated on 2026-10-22
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating efgartigimod as a replacement for intravenous immunoglobulin IVIG therapy in patients with stable, acetylcholine receptor antibody positive myasthenia gravis who depend on regular IVIG treatments. The study aims to determine if efgartigimod is as effective or not worse than IVIG, to assess patient preference between the two treatments, and to evaluate the safety and tolerability of efgartigimod given over six months.
Participants will stop IVIG one week before starting the study. Efgartigimod will be given as a one-hour intravenous infusion at a dose of 10 mgkg up to 1200 mg once weekly for four weeks, followed by a four-week break. This cycle will repeat four times until week 24. After the last treatment cycle, participants will be observed for two weeks before the study ends at week 26.
Throughout the 26 weeks, participants will have weekly evaluations of their myasthenia gravis symptoms using MG-ADL and MGQOL assessments. Researchers will monitor the sustained improvement in MG-ADL scores for at least four consecutive weeks as the primary outcome. Secondary outcomes include changes in QMG scores, quality of life measures, and the number of patients continuing efgartigimod at study end. Safety and tolerability of the treatment will also be closely monitored.
CONDITIONS
Brief Title
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Research Team
F
François Jacques, Doctor
V
Victorine Sikati Foko, Nurse
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.